BURLINGAME, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc., a biopharmaceutical company developing drugs for treating neurological disorders and diabetes, announced today positive preclinical data supporting expanded applications of AV-101, the Company’s first in-class prodrug that regulates critical NMDA receptors in the brain. The studies, which were performed in collaboration with Dr. Sophie Erhardt, Associate Professor of Pharmacology at the Karolinska Institute in Sweden, suggest that VistaGen’s AV-101 may have therapeutic potential for treating the symptoms of Parkinson’s disease and schizophrenia.
